logo
Abaxx Singapore Achieves ISO/IEC 27001:2022 Certification for Information Security Management

Abaxx Singapore Achieves ISO/IEC 27001:2022 Certification for Information Security Management

Globe and Mail23-05-2025
TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (' Abaxx ' or the ' Company '), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte. Ltd. (' Abaxx Singapore '), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, ' Abaxx Exchange ' and ' Abaxx Clearing '), and producer of the SmarterMarkets™ Podcast, today announced that Abaxx Singapore has achieved ISO/IEC 27001:2022 certification for its Information Security Management System (ISMS). The certification confirms that Abaxx Singapore's exchange and clearing infrastructure meets internationally recognized standards for securing data, managing risk, and supporting operational resilience.
The certification was awarded by Prescient Security, an independent global cybersecurity firm specializing in information security audits, compliance assessments, and penetration testing. ISO/IEC 27001:2022 is the global standard for information security management systems (ISMS), providing a framework for managing data security risks across people, processes, and technology. It is jointly published by the International Organization for Standardization (ISO) and the International Electrotechnical Commission (IEC).
As part of the certification process, Abaxx Singapore underwent a comprehensive audit of its IT systems, risk management protocols, and governance controls. The review confirmed alignment with global best practices for establishing, maintaining, and continually improving information security management frameworks.
'Achieving ISO/IEC 27001:2022 certification demonstrates that our exchange and clearing infrastructure aligns with the highest global standards for information security,' said Nancy Seah, CEO of Abaxx Exchange. 'For market participants, it provides assurance that the systems supporting trade execution, clearing, and data protection are built on a secure and resilient foundation. It also supports onboarding and ongoing operations with global institutions that require independently audited controls for risk, compliance, and business continuity.'
About Abaxx Technologies
Abaxx Technologies is building Smarter Markets: markets empowered by better tools, better benchmarks, and better technology to drive market-based solutions to the biggest challenges we face as a society, including the energy transition.
In addition to developing and deploying financial technologies that make communication, trade, and transactions easier and more secure, Abaxx is the indirect majority shareholder of Abaxx Singapore Pte. Ltd., the owner of Abaxx Exchange and Abaxx Clearing, and the parent company of wholly owned subsidiary Abaxx Spot Pte. Ltd., the operator of Abaxx Spot.
Abaxx Exchange delivers the market infrastructure critical to the shift toward an electrified, low-carbon economy through centrally-cleared, physically-deliverable futures contracts in LNG, carbon, battery materials, and precious metals, meeting the commercial needs of today's commodity markets and establishing the next generation of global benchmarks.
For more information about this press release, please contact:
Steve Fray, CFO
Tel: +1 647 490 1590
Media and I nvestor inquiries:
Abaxx Technologies Inc.
Investor Relations Team
Tel: +1 647 490 1590
E-mail: ir@abaxx.tech
Cautionary Statement Regarding Forward-Looking Information
This press release includes certain 'forward-looking statements' which do not consist of historical facts. Forward-looking statements include estimates and statements that describe Abaxx's future plans, objectives, or goals, including words to the effect that Abaxx expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as 'seeking', 'should', 'intend', 'predict', 'potential', 'believes', 'anticipates', 'expects', 'estimates', 'may', 'could', 'would', 'will', 'continue', 'plan' or the negative of these terms and similar expressions. Since forward-looking statements are based on current expectations and assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Abaxx, Abaxx does not provide any assurance that actual results will meet respective management expectations. Risks, uncertainties, assumptions, and other factors involved with forward- looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information.
Forward-looking information related to Abaxx in this press release includes, but is not limited to: Abaxx's objectives, goals or future plans; focus on risk management; and development of secure infrastructure. Such factors impacting forward-looking information include, among others: risks relating to the global economic climate; dilution; Abaxx's limited operating history; future capital needs and uncertainty of additional financing; the competitive nature of the industry; currency exchange risks; the need for Abaxx to manage its planned growth and expansion; the effects of product development and need for continued technology change; protection of proprietary rights; the effect of government regulation and compliance on Abaxx and the industry; acquiring and maintaining regulatory approvals for Abaxx's products and operations; the ability to list Abaxx's securities on stock exchanges in a timely fashion or at all; network security risks; the ability of Abaxx to maintain properly working systems; reliance on key personnel; global economic and financial market deterioration impeding access to capital or increasing the cost of capital; and volatile securities markets impacting security pricing unrelated to operating performance. In addition, particular factors which could impact future results of the business of Abaxx include but are not limited to: operations in foreign jurisdictions; protection of intellectual property rights; contractual risk; third-party risk; clearinghouse risk; malicious actor risks; third- party software license risk; system failure risk; risk of technological change; dependence of technical infrastructure; changes in the price of commodities; capital market conditions; and restriction on labor and international travel and supply chains in addition to the risk factors identified in the Company's most recent management discussion and analysis filed on SEDAR+. Abaxx has also assumed that no significant events occur outside of Abaxx's normal course of business.
Abaxx cautions that the foregoing list of material factors is not exhaustive. In addition, although Abaxx has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, or intended. When relying on forward- looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Abaxx has assumed that the material factors referred to in the previous paragraphs will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking statements and information contained in this press release represents the expectations of Abaxx as of the date of this press release and, accordingly, is subject to change after such date. Abaxx undertakes no obligation to update or revise any forward-looking statements and information, whether as a result of new information, future events or otherwise, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements and information. Cboe Canada does not accept responsibility for the adequacy or accuracy of this press release.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Adtran (ADTN) Q2 Revenue Jumps 17%
Adtran (ADTN) Q2 Revenue Jumps 17%

Globe and Mail

time3 minutes ago

  • Globe and Mail

Adtran (ADTN) Q2 Revenue Jumps 17%

Key Points Revenue (GAAP) exceeded expectations at $265.1 million in Q2 2025, up 17% year over year (GAAP). Non-GAAP operating margin rose to 3.0%, from 0.6% in Q2 2024. These 10 stocks could mint the next wave of millionaires › Adtran (NASDAQ:ADTN), a provider of fiber networking equipment and solutions for communications networks, released its second quarter 2025 results on August 5, 2025. The company delivered revenue (GAAP) of $265.1 million in Q2 2025—well above both management's guidance and analyst GAAP estimates of $260.2 million. Non-GAAP operating margin improved to 3.0%, and Free cash flow (non-GAAP) increased from $3.9 million in Q2 2024 to $18.3 million. However, adjusted earnings per share (non-GAAP) were break-even, and profitability remains a work in progress, despite year-over-year improvement. The quarter showed clear top-line outperformance, as GAAP revenue of $265.1 million exceeded the analysts' estimate by approximately 1.9%, but sustainable profit levels and margin expansion are areas to watch. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) $(0.00) N/A $(0.13) 100.0 % Revenue (GAAP) $265.1 million $260.2 million $226.0 million 17.3 % Gross Margin (Non-GAAP) 41.4 % 41.8 % (0.4 pp) Operating Margin (Non-GAAP) 3.0 % 0.6 % 2.4 pp Free Cash Flow (Non-GAAP) $18.3 million $3.9 million 369.2 % Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report. What Adtran Does and Where It's Focused Adtran builds and supplies hardware and software to companies and telecom carriers that need high-speed, fiber-optic-based network infrastructure. Its main products range from access platforms that connect homes and businesses to fiber grids, to tools that help manage and secure growing network traffic. Its recent focus revolves around becoming a leader in fiber networking, expanding into international markets, and tightening operational efficiency. Critical to success are Adtran's innovation pipeline—in other words, how quickly and effectively it develops new products—and its ability to win share from competitors. The company also emphasizes investment in research and development, which supports future product launches and maintains technical differentiation in a crowded field. Quarter in Review: Revenue Beat, Mixed Margins, and Cash Progress Results exceeded both internal guidance and outside expectations, with total revenue (GAAP) up 17% year-over-year compared to Q2 2024. The Network Solutions business—which focuses on fiber networking products—saw notable growth, rising 22.5% from $179.2 million in Q2 2024 to $219.5 million (GAAP). However, the Services & Support segment (GAAP) declined 2.6% to $45.6 million compared to Q2 2024, capturing share in what management describes as 'key areas,' even though details by region or customer group were not provided. Margins (GAAP and non-GAAP) moved in a positive direction on a year-over-year basis, though the picture is not uniformly strong. Non-GAAP operating margin improved to 3.0%, compared with 0.6% in the prior-year quarter, while non-GAAP gross margin held above 41%. Compared with the prior quarter, though, both GAAP and non-GAAP gross and operating margins fell slightly, suggesting some pressure on profitability despite better sales. With cost savings from its Business Efficiency Program now largely realized. Operationally, the company made progress in generating cash. Operating cash flow (GAAP) was $32.2 million, up from $19.9 million in Q2 2024. Free cash flow (non-GAAP) jumped to $18.3 million from $3.9 million in Q2 2024. Cash and equivalents (GAAP) were $106.3 million as of June 30, 2025, reflecting stronger cash generation on growing sales. Research and development spending (GAAP) came to $51.9 million, down from $60.4 million in Q2 2024. However, Selling, general, and administrative costs (GAAP) were stable year over year. Fiber Networking Leadership and Competition Adtran's main product families include fiber access platforms—hardware systems that deliver high-speed fiber connections to homes and businesses. As stated by CEO Tom Stanton: 'We delivered strong Q2 2025 results with GAAP revenue growth that exceeded expectations.' The focus on network core-to-edge solutions positions the company competitively as bandwidth needs rise with trends like cloud adoption and artificial intelligence. Competitive pressure remains intense, with larger network equipment providers such as Nokia, Huawei, and Ciena also vying for market dominance. Maintaining non-GAAP gross margins above 40% suggests the company continues to compete on technology rather than price alone. Management reported that business efficiency initiatives are now largely complete. The company reported ongoing material weaknesses in its internal controls for financial reporting. Adtran does not currently pay a dividend. Looking Ahead: Guidance and Key Areas for Investors Management provided a financial outlook, guiding revenue to a range of $270.0 million to $280.0 million. At the midpoint, this projects sequential growth of 3.7%. Non-GAAP operating margin is expected in the 3.0% to 7.0% range, signaling intent to build on the improvement seen this period. However, no additional specifics on bookings or detailed segment expectations were shared. Investors should monitor whether margin progress continues, as both gross and operating margins (GAAP and non-GAAP) softened slightly from the previous quarter. Areas to watch in the months ahead include the sustainability of Network Solutions growth, R&D spending levels, and whether the company can make further headway toward profitability. Management remains focused on increasing efficiency and broadening its fiber portfolio to support long-term strategic goals. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of August 4, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

LifeMD (LFMD) Q2 Revenue Rises 23%
LifeMD (LFMD) Q2 Revenue Rises 23%

Globe and Mail

time26 minutes ago

  • Globe and Mail

LifeMD (LFMD) Q2 Revenue Rises 23%

Key Points Revenue grew 23% year over year (GAAP) in Q2 2025, but missed analyst estimates by $4.1 million (GAAP). The telehealth segment achieved 30.0% revenue growth, with Adjusted EBITDA rising 560%. Management cut full-year 2025 guidance across all major metrics due to Rex MD challenges, lowering total revenue guidance to $250 million–$255 million, telehealth revenue to $195 million–$200 million, adjusted EBITDA to $27 million–$29 million, and telehealth adjusted EBITDA to $14 million–$16 million. These 10 stocks could mint the next wave of millionaires › LifeMD (NASDAQ:LFMD), a telehealth platform specializing in virtual care and digital health subscriptions, reported its second quarter 2025 financial results on August 5, 2025. Revenue (GAAP) was $62.2 million, up 23% from the same period last year but $4.1 million below consensus estimates (GAAP). Earnings per share (EPS) came in at a loss of $0.06 (GAAP), which was also below analyst expectations by $0.0517 (GAAP). Despite year-over-year expansion in core business metrics, results missed both revenue and GAAP earnings projections. The quarter showcased strong telehealth growth and improved operational profitability, but also included a guidance reduction for the full year, pointing to segment-specific pressures, especially within men's health. Overall, the period highlighted robust subscriber and adjusted EBITDA gains alongside mounting challenges in forecasting and segment execution. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) ($0.06) ($0.01) ($0.19) Improved Revenue (GAAP) $62.2 million N/A $50.7 million 22.8 % Adjusted EBITDA $7.1 million $2.2 million 223% Telehealth Revenue $48.6 million $37.4 million 30.0 % Telehealth Adjusted EBITDA $3.4 million $0.5 million 580 % Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Understanding LifeMD's Business Model and Key Growth Factors LifeMD delivers virtual healthcare services directly to consumers in all 50 states, focusing on subscription-based telehealth for chronic condition management, primary care, and specialty health segments. It operates two main businesses: a telehealth segment delivering care through a vertically integrated platform (including pharmacy and labs), and WorkSimpli, a smaller software platform targeting administrative business solutions. In recent quarters, LifeMD has sharpened its emphasis on recurring telehealth subscriptions, platform expansion, and expansion into new clinical verticals such as behavioral and women's health. Key drivers for success include strong regulatory compliance, platform-driven patient retention, and the ability to introduce services efficiently at scale. Partnerships with healthcare brands and continued technology investment also feature heavily among its strategies for differentiation and sustainable growth. Quarterly Highlights and Segment Performance LifeMD's total revenue (GAAP) climbed 23% year over year, led by a 30% surge in telehealth segment revenue and a significant jump in operational profitability, as reflected by adjusted EBITDA (non-GAAP) increasing to $7.1 million from $2.2 million in Q2 2024. Active telehealth subscribers reached nearly 297,000, up 16% year over year. However, while overall revenue grew, the outcome was $4.1 million behind analyst forecasts on a GAAP basis, highlighting gaps versus external expectations. The telehealth segment continues to be LifeMD's main growth engine. Telehealth Adjusted EBITDA, a non-GAAP measure used to assess core profitability before certain accounting deductions, surged 560% to $3.4 million from the year-ago period. The segment benefited from strong demand for subscription-based chronic care, weight management, and expanded men's health services such as hormone therapy. Management reported that new offerings in behavioral and women's health delivered limited revenue during the quarter, but these areas are expected to contribute more materially over time. WorkSimpli revenue (GAAP) edged up 3% compared to the same period last year, active subscribers in this segment fell 6%, as the company shifted its strategy to focus on higher-value, longer-term clients rather than maximizing subscriber count. As a result, WorkSimpli's adjusted EBITDA more than doubled compared to Q2 2024, underscoring the company's drive to maximize cash flow from this asset ahead of any potential future divestiture. Gross margin, which measures the proportion of revenue retained after accounting for direct service costs, slipped to 88% from 90% last year (GAAP). Management attributed this margin compression chiefly to changes in revenue mix, as the telehealth segment's component services grew at varying rates. Operating cash flow was robust, exceeding $8 million, and the company ended the period with a cash position of $36.2 million after fully repaying its senior debt post-quarter. LFMD does not currently pay a dividend. Key Business Developments, Risks, and Strategic Initiatives Several forces shaped LifeMD's second quarter. First, the company's rapid expansion in telehealth continued as it grew recurring, subscription-based revenue streams and lifted its active user base. Telehealth subscriptions remain the backbone of LifeMD's financial model, accounting for most segment revenue. The company took notable steps to widen its clinical reach. It launched a national behavioral health service, providing both real-time (synchronous) and on-demand (asynchronous) care for mental health. Through a recent acquisition, it is rolling out subscription-based virtual women's health programs, starting with VIP concierge offerings and plans to extend to broader insurance-supported and cash-pay options. In parallel, LifeMD enhanced its LifeMD+ membership program to aggregate telehealth, pharmacy, laboratory, and wellness services under one umbrella for better patient retention. From a financial perspective, cost discipline played a visible role, as selling and marketing expenses increased, but general and administrative spending was trimmed year on year. The company succeeded in improving net losses (GAAP) from $7.7 million to $2.9 million versus Q2 2024. and more than tripled its overall Adjusted EBITDA (non-GAAP). At the same time, margin pressure appeared, as gross margins (GAAP) dipped to 88% from 90% in Q2 2024, reflecting a greater share of lower-margin revenue. Legal and regulatory risk remains the most notable external issue, particularly surrounding LifeMD's reliance on the supply of GLP-1 weight-loss medications. Shifts in either FDA policy or supply dynamics could have a direct effect on future results. Strategic partnerships made headlines this quarter. LifeMD moved forward with collaborations with weight management drug providers LillyDirect and NovoCare, aimed at helping patients access branded therapies like Wegovy and Zepbound when lacking insurance. The company does not receive financial incentives from these collaborations, which it views as a competitive advantage in virtual obesity care. Early revenue from these verticals remains small, and integration is ongoing. On the technology front, the company remains aggressive, capitalizing on its proprietary telehealth infrastructure, pharmacy network, software, and integrated patient experience. Platform upgrades, enhanced CRM (customer relationship management) systems, and new patient-facing technology continued as investment priorities, fueling opportunities to bring new services to market more quickly and deepen relationship-based retention. Despite top-line growth, mounting uncertainty underpinned the revised full-year outlook. In response to challenges in the Rex MD men's health brand -- involving both business execution and regulatory complexity -- LifeMD lowered its forward guidance for total revenue, telehealth revenue, and Adjusted EBITDA for the full year. Guidance now stands at $250–$255 million in total revenue (GAAP basis), $195–$200 million telehealth revenue (GAAP, full year), and $27–$29 million in Adjusted EBITDA for the full year, as both market conditions and regulatory situations continue evolving. Looking Forward: Guidance and Investor Considerations For Q3 2025, LifeMD's leadership projects total revenue between $61 million and $63 million, with telehealth revenue expected to contribute $48 million to $50 million and Adjusted EBITDA ranging from $6 million to $7 million. Management does not expect a material one-time boost from newly launched verticals or drug collaborations for the remainder of the year, though moderate growth is reflected from early ramp-up in women's and behavioral health. These updates represent a notable reduction from previous management forecasts, reflecting ongoing impacts from earlier Rex MD disruptions. The company's near-term performance will depend on its ability to stabilize subscriber growth, control marketing and service costs, and successfully integrate new verticals without additional unforeseen challenges. Ongoing legal actions and changing rules around compounded drugs remain watch points for the business and shareholders alike. LFMD does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store